Advertisement
Advertisement
U.S. markets open in 5 hours 3 minutes
Advertisement
Advertisement
Advertisement
Advertisement

LianBio (LIAN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.0000+0.3900 (+14.94%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close2.6100
Open2.8100
Bid0.0000 x 1000
Ask0.0000 x 1200
Day's Range2.7000 - 3.0800
52 Week Range2.1000 - 16.3700
Volume818,936
Avg. Volume260,237
Market Cap325.062M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.8960
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.78
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LIAN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • LianBio
    Daily – Vickers Top Buyers & Sellers for 04/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Completed enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three additional registration-enabling programs to begin in China by year-end 2022Cash balance of $349.4 million at the end of second quarter 2022 with runway into the second half of 2024 SHANGHAI, China and PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company de

  • GlobeNewswire

    LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

    • Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of mavacamten in China SHANGHAI, China and PRINCETON, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the completion of enrollment in the Phase 3 EXPLORER-CN clinical study of mavacamten in Chinese

  • GlobeNewswire

    LianBio to Participate in June Investor Events

    SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: Jefferies Healthcare Conference – June 10, 2022, at 11:00 am ETGoldman Sachs Healthcare Conference – June 15, 2022, at 2:40 pm PT Live audio webcasts o

Advertisement
Advertisement